To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque Psoriasis

NCT07008547 | Completed Phase 3

• 1 other identifier: BCD-085-CN01
• Study Type: interventional
• Target: 202
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to To evaluate the efficacy of subcutaneous (SC) Netakimab in adult Chinese patients with moderate to severe plaque psoriasis. Researchers will compare Netakimab to placebo to see if Netakimab works to treat plaque psoriasis.

Conditions

Plaque Psoriasis

Outcome Measures

Primary Outcomes (2)

• Proportion of subjects achieving PASI75

  Proportion of subjects with a Psoriatic Area and Severity Index (PASI) score improved by at least 75% (to achieve a PASI 75 response) relative to the baseline PASI score at Week 12

  at week 12

• Proportion of subjects achieving sPGA0/1

  Proportion of subjects with a sPGA(Static Physician Global Assessment) either 0 or 1 at Week 12

  at week 12

Secondary Outcomes (5)

• Proportion of subjects achieving PASI75

  through out the study(From baseline to Week 62)

• Proportion of subjects achieving PASI90

  through out the study(From baseline to Week 62)

• Proportion of subjects achieving PASI100

  through out the study(From baseline to Week 62)

• Proportion of subjects achieving PGA

  through out the study(From baseline to Week 62)

• Changes from baseline in NAPSI score

  through out the study(From baseline to Week 52)

Study Arms (2)

Netakimab

EXPERIMENTAL

Netakimab administered by subcutaneous injection until Week 52

Biological: Netakimab

Placebo

PLACEBO COMPARATOR

Placebo administered by subcutaneous injection until Week 12 then Netakimab subcutaneous injection until 52 week

Biological: Netakimab; Drug: Placebo

Interventions

Netakimab BIOLOGICAL

Netakimab administered subcutaneously

Netakimab; Placebo

Placebo DRUG

Placebo administered subcutaneously

Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients must voluntarily sign and date an Informed Consent Form (ICF) approved by the Ethics Committee (IEC) prior to any study-related procedures. The legal representative may also be asked to sign the ICF in accordance with local laws and regulations if necessary.
• Male or female, ≥ 18 years old at the time of signing the ICF.
• Patients with plaque psoriasis diagnosed at least for 6 months prior to signing the ICF.
• Patients who have inadequate response or intolerance to phototherapy or systemic drug therapy (biological or non-biological agents other than IL-17/IL-17R inhibitors) for psoriasis, or meet the above treatment indications in the opinion of the investigator.
• Patients with psoriasis involved body surface area (BSA) of 10% or more, PASI score of 10 or more, and sPGA score of 3 or more at screening.
• WOCBP have a negative serum pregnancy test (no pregnancy test is required for women of non-childbearing potential).
• Patients of childbearing potential and their partners must implement reliable contraceptive measures as specified in the protocol from signing the ICF until 20 weeks after the last dose of study treatment (see Appendix 10 for details).
• Patients who have the ability to follow protocol procedures as judged by the investigator.

You may not qualify if:

• Patients with other types of psoriasis (e.g., erythrodermic psoriasis, pustular psoriasis, guttate psoriasis) or any other skin disorders (e.g., eczema) that may affect the treatment/evaluation of psoriasis, and patients with drug-induced psoriasis or a history of drug-induced psoriasis at screening.
• Patients who are unable or unwilling to undergo repeated subcutaneous injection and venipuncture (e.g., because of poor tolerability or lack of venous access).
• Patients who have received the prohibited drugs or vaccines as specified in the protocol:
• Patients with hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, human immunodeficiency virus (HIV) infection, treponema pallidum (TP) infection.
• Patients meeting any of the following criteria for laboratory tests at screening: serum creatinine (Cr) \> 1.5 × upper limit of normal (ULN); alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) \> 2.5 × ULN; total bilirubin (TBIL) \> 1.5 × ULN; white blood cell (WBC) count \< 3.0 × 109/L; absolute neutrophil count (ANC) \< 2.0 × 109/L; platelet (PLT) count \< 100 × 109/L; hemoglobin (Hb) \< 90 g/L.
• Patients with any psychiatric disorders, including serious depressive disorder, or history of strong suicidal ideation or suicide intention; or clinically significant symptoms of depression (Beck score ≥ 16 at screening), which require intervention treatment determined by a specialist.
• Patients with history or evidence of alcohol or drug abuse.
• Patients with active tuberculosis infection or history of tuberculosis, or current latent tuberculosis infection \[positive for interferon gamma release assay (QuantiFERON TB-Gold or T-SPOT etc.)\].
• Patients with other diseases that may affect the assessment of psoriasis or any other underlying disease (including, but not limited to, clinically significant cardiac, hepatic, renal, respiratory, immune, neurological, endocrine, metabolic, blood, gastrointestinal, or psychiatric disorders) that, in the opinion of the investigator, study treatment may place the patient at additional risks
• Patients with current or previous malignant tumor within the past 5 years \[except adequately treated (cured) squamous cell carcinoma or basalioma, cervical uteri cancer in situ or in situ breast ductal carcinoma\].
• Patients with known history of serious allergies (allergies to two or more drugs or systemic allergic reactions).
• Patients with known allergies or intolerance to monoclonal antibody drugs or any other component of the investigational product or placebo.
• Patients who have had major surgery within 30 days prior to screening or scheduled for major surgeries at any time during the study.
• Patients with active infection or medical history:
• Patients with epileptic seizure or the history of epileptic seizure.

Sponsors & Collaborators

• SPH-BIOCAD (HK) Limited: lead

Study Sites (1)

Peking University People's Hospital

Beijing, Beijing Municipality, China

Location

MeSH Terms

Interventions

netakimab

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 28, 2025
• First Posted: June 6, 2025
• Study Start: July 30, 2024
• Primary Completion: March 28, 2025
• Study Completion: June 13, 2025
• Last Updated: April 15, 2026

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)